WHO says AstraZeneca benefits outweigh risks; assessing latest data


  • World
  • Wednesday, 07 Apr 2021

A vial of AstraZeneca COVID-19 vaccine is seen at a vaccination center, amid the coronavirus disease outbreak, in Ronquieres, Belgium April 6, 2021. REUTERS/Yves Herman

GENEVA (Reuters) - The World Health Organization expects there will be no reason to change its assessment that the benefits of the AstraZeneca vaccine against COVID-19 outweigh any risks, its regulatory director said on Tuesday.

The WHO is closely studying the latest data alongside European and other regulators, in light of reports of blood clots among people who have been vaccinated, said Rogerio Gaspar, WHO director of regulation and prequalification.

A senior official at Europe's medicines regulator has said there is a clear "association" between AstraZeneca's COVID-19 vaccine and very rare blood clots in the brain, though the direct cause of the clots is still unknown.

The European Medical Agency (EMA) said in a statement after the comments by Marco Cavaleri, chair of its vaccine evaluation team, that it was still conducting a review of the vaccine and expected to announce its findings on Wednesday or Thursday.

Gaspar said the WHO expects to reach a fresh assessment on Wednesday or Thursday, after its own vaccine safety advisory group meets, but does not believe there will be a reason to change its advice that the benefits outweigh any risks.

"What we can say is that the appraisal that we have for the moment - and this is under consideration by the experts - is that the benefits-risk assessment for the vaccine is still largely positive," he told a Geneva news conference.

"We continue to see a number of events that are rare events linking thrombocytopenia to thromboembolic events and those rare events are now being categorised in terms of the diagnostics, in terms of the population, in terms of the distribution within the population," he said.

WHO was in touch with various national and regional expert committees that will decide on the vaccine's regulatory status, Gaspar said.

"For the time being there is no evidence that the benefit-risk assessment for the vaccine needs to be changed," he added.

(Reporting by John Miller and Stephanie Nebehay in Geneva; Writing by Peter Graff; Editing by Kevin Liffey and Matthew Lewis)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In World

France's Macron asks prime minister to propose new government to be named in July
Ukraine will fight on from higher ground after pullback, spy chief says
Putin promises Belarus nuclear-capable missiles to counter 'aggressive' West
One in two households in Greece struggling to cover energy needs: survey
Commonwealth ends summit with call for action on climate change, trade
Russian military says it has full control over Sievierodonetsk
U.S. Treasury's Adeyemo discussed Russia sanctions implementation in Turkey visit
Ecuador defender Arboleda in doubt for World Cup
U.S. wins women's 4x100m medley relay at FINA worlds
Italy wins men's 4x100m medley relay at FINA worlds

Others Also Read